{"id":"NCT01364428","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus","officialTitle":"A Trial Comparing the Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Subjects With Type 2 Diabetes Mellitus (BEGINâ„¢: COMPARE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2011-06-02","resultsPosted":"2015-11-18","lastUpdate":"2017-03-06"},"enrollment":373,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"insulin degludec","otherNames":[]}],"arms":[{"label":"IDeg 200 U/mL","type":"EXPERIMENTAL"},{"label":"IDeg 100 U/mL","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy and safety of two different formulations of insulin degludec (IDeg) in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Change in Glycosylated Haemoglobin (HbA1c)","timeFrame":"Week 0, Week 22","effectByArm":[{"arm":"IDeg 200 U/mL","deltaMin":-0.79,"sd":0.89},{"arm":"IDeg","deltaMin":-0.7,"sd":0.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":45,"countries":["United States"]},"refs":{"pmids":["24518180"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":184},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea"]}}